ArticleCellular oncology (Dordrecht, Netherlands)2024

PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.

Xianglai Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.